Pharmacy major Walgreens Boot Alliance Inc. reported Thursday a hefty loss in its first quarter, mainly hit by charges related to opioid-related claims and weak sales. Adjusted earnings, and sales, however, topped market estimates mainly benefited by strong cough, cold, flu sales. Looking ahead, the company maintained its fiscal 2023 earnings view, and raised sales guidance.
In pre-market activity on Nasdaq, Walgreens shares were losing around 2.2 percent to trade at $36.65.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com